NYMX insider trading

NYMOX PHARMACEUTICAL CORP: insider trade history from SEC Form 4 filings.

Total Form 4 trades
361
Last 90 days
0
Buys / sells
99% / 1%
Market cap
—

NYMX insider activity at a glance

FilingIQ tracks 361 insider transactions for NYMX in filings since Sep 8, 2015. The most recent transaction is dated Apr 27, 2023.

Across the full history, 359 open-market purchases and 2 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NYMX insider trades is 41.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Latest NYMX Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Politicians who have traded NYMX

Frequently asked

How many insider trades does FilingIQ track for NYMX?
FilingIQ tracks 361 Form 4 insider transactions for NYMX (NYMOX PHARMACEUTICAL CORP), covering filings from Sep 8, 2015 onwards. 0 of those are dated within the last 90 days.
Are NYMX insiders net buyers or net sellers?
Across the full Form 4 history for NYMX, 359 transactions (99%) were open-market purchases and 2 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NYMX insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

Methodology & sources

Every NYMX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.